Population pharmacogenomics and personalized medicine research in hungary: Achievements and lessons learned

Research output: Contribution to journalArticle

Abstract

There have been a number of notable strides in Hungary in the field of population pharmacogenomics. This paper aims to summarize and share the recent experiences in population genomics and personalized medicine in Hungary with leaders of the Genomic National Technology Platform. The present day Hungary differs from other populations in the region as Hungary was established some 1100 years ago, with founders of the ancestral Hungarian population originating from the east side of the Urals. Additionally, the Roma population of about 700,000 represents the largest ethnic minority living in Hungary. In a series of investigations, we found significant differences between the Hungarian and Roma populations in clinically relevant pharmacogenomics targets such as VKORC1 and CYP2C9 genes. Pharmacogenomics applications are also of interest from the standpoint of biomarker-guided drug discovery in Hungary which we highlight briefly in this paper. Regulatory, ethical and economic aspects of genomics are other dimensions crucial for efficient transition of basic genomics discoveries from laboratory to the clinic. Importantly, Hungary has a Parliamental Act for regulation of genetic diagnostic and research test procedures, and for regulation of biobanks since 2008. Diagnostic molecular pharmacogenomics tests are reimbursed from the same insurance budget as with the other molecular biology based tests in Hungary. Personalized medicine diagnostics require further considerations on how best to integrate and reimburse them in routine healthcare as this new field evolves in Hungary.

Original languageEnglish
Pages (from-to)194-201
Number of pages8
JournalCurrent Pharmacogenomics and Personalized Medicine
Volume8
Issue number3
Publication statusPublished - 2010

Fingerprint

Precision Medicine
Hungary
Pharmacogenetics
Research
Population
Roma
Genomics
Metagenomics
Genetic Research
Molecular Pathology
Budgets
Drug Discovery
Insurance
Routine Diagnostic Tests
Molecular Biology
Biomarkers
Economics
Technology
Delivery of Health Care

Keywords

  • CYP2C9 and VKORC1 variations
  • Hungarians and roma
  • Personalized therapy
  • Population pharmacogenomics
  • Warfarin

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Pharmacology
  • Molecular Biology
  • Genetics(clinical)

Cite this

@article{6521d66814c1414eb110cb1f3b0b052b,
title = "Population pharmacogenomics and personalized medicine research in hungary: Achievements and lessons learned",
abstract = "There have been a number of notable strides in Hungary in the field of population pharmacogenomics. This paper aims to summarize and share the recent experiences in population genomics and personalized medicine in Hungary with leaders of the Genomic National Technology Platform. The present day Hungary differs from other populations in the region as Hungary was established some 1100 years ago, with founders of the ancestral Hungarian population originating from the east side of the Urals. Additionally, the Roma population of about 700,000 represents the largest ethnic minority living in Hungary. In a series of investigations, we found significant differences between the Hungarian and Roma populations in clinically relevant pharmacogenomics targets such as VKORC1 and CYP2C9 genes. Pharmacogenomics applications are also of interest from the standpoint of biomarker-guided drug discovery in Hungary which we highlight briefly in this paper. Regulatory, ethical and economic aspects of genomics are other dimensions crucial for efficient transition of basic genomics discoveries from laboratory to the clinic. Importantly, Hungary has a Parliamental Act for regulation of genetic diagnostic and research test procedures, and for regulation of biobanks since 2008. Diagnostic molecular pharmacogenomics tests are reimbursed from the same insurance budget as with the other molecular biology based tests in Hungary. Personalized medicine diagnostics require further considerations on how best to integrate and reimburse them in routine healthcare as this new field evolves in Hungary.",
keywords = "CYP2C9 and VKORC1 variations, Hungarians and roma, Personalized therapy, Population pharmacogenomics, Warfarin",
author = "Csilla Sipeky and Gyorgy Keri and Andras Kiss and Laszlo Kopper and Andras Matolcsy and Jozsef Timar and Molnar, {Maria Judit} and Laszlo Nagy and Gyorgy Nemeth and Istvan Petak and Istvan Rasko and Andras Falus and Bela Melegh",
year = "2010",
language = "English",
volume = "8",
pages = "194--201",
journal = "Current Pharmacogenomics and Personalized Medicine",
issn = "1875-6921",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Population pharmacogenomics and personalized medicine research in hungary

T2 - Achievements and lessons learned

AU - Sipeky, Csilla

AU - Keri, Gyorgy

AU - Kiss, Andras

AU - Kopper, Laszlo

AU - Matolcsy, Andras

AU - Timar, Jozsef

AU - Molnar, Maria Judit

AU - Nagy, Laszlo

AU - Nemeth, Gyorgy

AU - Petak, Istvan

AU - Rasko, Istvan

AU - Falus, Andras

AU - Melegh, Bela

PY - 2010

Y1 - 2010

N2 - There have been a number of notable strides in Hungary in the field of population pharmacogenomics. This paper aims to summarize and share the recent experiences in population genomics and personalized medicine in Hungary with leaders of the Genomic National Technology Platform. The present day Hungary differs from other populations in the region as Hungary was established some 1100 years ago, with founders of the ancestral Hungarian population originating from the east side of the Urals. Additionally, the Roma population of about 700,000 represents the largest ethnic minority living in Hungary. In a series of investigations, we found significant differences between the Hungarian and Roma populations in clinically relevant pharmacogenomics targets such as VKORC1 and CYP2C9 genes. Pharmacogenomics applications are also of interest from the standpoint of biomarker-guided drug discovery in Hungary which we highlight briefly in this paper. Regulatory, ethical and economic aspects of genomics are other dimensions crucial for efficient transition of basic genomics discoveries from laboratory to the clinic. Importantly, Hungary has a Parliamental Act for regulation of genetic diagnostic and research test procedures, and for regulation of biobanks since 2008. Diagnostic molecular pharmacogenomics tests are reimbursed from the same insurance budget as with the other molecular biology based tests in Hungary. Personalized medicine diagnostics require further considerations on how best to integrate and reimburse them in routine healthcare as this new field evolves in Hungary.

AB - There have been a number of notable strides in Hungary in the field of population pharmacogenomics. This paper aims to summarize and share the recent experiences in population genomics and personalized medicine in Hungary with leaders of the Genomic National Technology Platform. The present day Hungary differs from other populations in the region as Hungary was established some 1100 years ago, with founders of the ancestral Hungarian population originating from the east side of the Urals. Additionally, the Roma population of about 700,000 represents the largest ethnic minority living in Hungary. In a series of investigations, we found significant differences between the Hungarian and Roma populations in clinically relevant pharmacogenomics targets such as VKORC1 and CYP2C9 genes. Pharmacogenomics applications are also of interest from the standpoint of biomarker-guided drug discovery in Hungary which we highlight briefly in this paper. Regulatory, ethical and economic aspects of genomics are other dimensions crucial for efficient transition of basic genomics discoveries from laboratory to the clinic. Importantly, Hungary has a Parliamental Act for regulation of genetic diagnostic and research test procedures, and for regulation of biobanks since 2008. Diagnostic molecular pharmacogenomics tests are reimbursed from the same insurance budget as with the other molecular biology based tests in Hungary. Personalized medicine diagnostics require further considerations on how best to integrate and reimburse them in routine healthcare as this new field evolves in Hungary.

KW - CYP2C9 and VKORC1 variations

KW - Hungarians and roma

KW - Personalized therapy

KW - Population pharmacogenomics

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=78649280665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649280665&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:78649280665

VL - 8

SP - 194

EP - 201

JO - Current Pharmacogenomics and Personalized Medicine

JF - Current Pharmacogenomics and Personalized Medicine

SN - 1875-6921

IS - 3

ER -